Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: A post hoc analysis from placebo-controlled Phase 3 studies with secukinumab
Ther Adv Musculoskelet Dis. 2025;17:1–7
Brandt-Jürgens et al. identified a difference between the incidence rates of uveitis in patients with PsA or axSpA when treated with secukinumab compared to placebo. The authors conducted a post hoc analysis of 11 placebo-controlled clinical trials which has observed that uveitis incidences in patients with PsA are consistent with clinical trial data, and patients with axSpA show a lower incidence of uveitis compared to other publications.
Patients in both cohorts reported the severity of uveitis as mild to moderate and no incidences led to discontinuation of secukinumab. This data enhances our understanding of uveitis in patients with PsA and axSpA.
Keywords:
